表紙
市場調査レポート

リネゾリドの中国市場

Investigation Report on China Linezolid Market, 2010-2019

発行 China Research and Intelligence 商品コード 332302
出版日 ページ情報 英文 20 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
リネゾリドの中国市場 Investigation Report on China Linezolid Market, 2010-2019
出版日: 2015年06月04日 ページ情報: 英文 20 Pages
概要

リネゾリドは、Pharmacia & Upjohnによって開発された合成オキサゾリジノン化合物です。2000年にFDAの承認を取得したリネゾリドの同年の売上げは、1億5000万米ドルでしたが、2013年から2014年の期間のには、13億5000万米ドルに達しました。近年の中国市場におけるリネゾリドの売上げは、非常に不安定で、2014年の売上げは9300万人民元で、2010年当時に記録した売上げ (1億1300万人民元) を下回りました。

当レポートでは、中国におけるリネゾリド市場の規模と今後の見通し、主要製薬会社および剤形別の市場シェア、販売価格などの情報を提供しています。

第1章 リネゾリドの関連概念

  • 適応
  • 世界市場における販売状況

第2章 中国におけるリネゾリドの市場プロファイル

  • リネゾリドの特許および承認状況
  • 主要製薬会社
  • 市場規模

第3章 中国におけるリネゾリドの販売状況調査

  • 販売額
    • 総販売額
    • 地域別の販売額
  • 販売量
    • 総販売量
    • 地域別の販売数

第4章 中国におけるリネゾリドの主要製薬会社の市場シェア調査

  • 販売額ベースの市場シェア
  • 販売量ベースの市場シェア

第5章 中国におけるリネゾリドの剤形に関する調査

  • 剤形別の市場シェア:販売額ベース
  • 剤形別の市場シェア:販売量ベース

第6章 中国の病院におけるリネゾリドの基準価格

  • Fresenius Kabi
  • Pfizer Inc. (米国)

第7章 中国市場におけるリネゾリドの主要製薬会社

  • Pfizer Inc. (米国)
  • Fresenius Kabi
  • Pharmacia & Upjohn

第8章 中国におけるリネゾリドの市場見通し

  • 市場規模の予測
  • 競合情勢の予測
目次
Product Code: 1506194

Infection caused by bacteria that are resistant to antibiotics is spreading over the world with increasing infection rate and mortality rate, which has posed a serious threat to human health. In 2004, National Nosocomial Infection Surveillance reported that people infected by Methicillin Resistant Staphylococcus Aureus (MRSA) take up 63.3% of all patients with nosocomial infection of staphylococcus aureus. Among staphylococcus aureus infections, MRSA separation rate occupied 69.2%. The mortality rate of MRSA infection is 20 times of Methicillin Sensitive Staphylococcus Aureus (MSSA).

Linezolid, a synthetic oxazolidinone, was developed by Pharmacia & Upjohn. In 2000, it was approved by FDA to be used for infection caused by gram-positive coccus, including suspected or confirmed Hospital Acquired Pneumonia (HAP) caused by MRSA, Community Acquired Pneumonia (CAP), skin and soft tissue infections (SSTI) and vancomycin-resistant enterococcus infection. Linezolid brought in sales revenue of USD 150 million in the same year it entered market and its sales in the global market during the period of 2013-2014 reached up to USD 1350 million. In China, linezolid market has long been monopolized by foreign pharmaceutical corporations. Since the patent for linezolid's crystal form shall expire in 2021, its price stays high.

Linezolid develops fast after entering China. In recent years, its sales value in the Chinese market has been extremely unstable, falling from CNY 113 million in 2010 to CNY 93 million in 2014. Currently, linezolid in the Chinese market comes from the following three companies: Pfizer Inc., Fresenius Kabi and Pharmacia & Upjohn, among which Pfizer has the largest market share of 69.92% with sales in 2014 reaching up to CNY 64.24 million.

Generally speaking, linezolid enjoys a vast demand in China.

Readers can get at least the following information through this report:

  • market size of linezolid in China
  • major manufacturers of linezolid in the Chinese market and their market share
  • retail price of linezolid in China
  • market outlook of linezolid in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-infectious agents
  • investors/ research institutions interested in Chinese medicine market
  • any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Linezolid

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Linezolid in China

  • 2.1. Patent and Approval Status of Linezolid in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Linezolid in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Linezolid in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Linezolid in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Linezolid in Chinese Hospitals in 2014

  • 6.1. Fresenius Kabi
  • 6.2. Pfizer Inc. (the US)

7. Major Manufacturers of Linezolid in Chinese Market, 2010-2014

  • 7.1. Pfizer Inc. (the US)
  • 7.2. Fresenius Kabi
  • 7.3. Pharmacia & Upjohn

8. Market Outlook of Linezolid in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Linezolid in China
  • Chart Approval Information of Linezolid in China
  • Chart Sales Status of Linezolid in Chinese Market, 2010-2014
  • Chart Sales Value of Linezolid in China, 2010-2014
  • Chart Sales Value of Linezolid in Some Regions in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of Linezolid for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Linezolid Made by Pfizer (the US) in China, 2010-2014
  • Chart Sales Value and Market Share of Linezolid Made by Fresenius Kabi (NO) in China, 2010-2014
  • Chart Sales Value and Market Share of Linezolid Injections in China, 2010-2014
  • Chart Sales Value and Market Share of Linezolid Tablets in China, 2010-2014
  • Chart Price of Linezolid Made by Fresenius Kabi in Some Chinese Cities in 2014
  • Chart Price of Linezolid Made by Pfizer Inc. (the US) in Some Chinese Cities in 2014
Back to Top